Suppr超能文献

居家或院内宫颈成熟度处理的前瞻性队列研究及流程评估(CHOICE)研究:研究方案。

Cervical ripening at home or in-hospital-prospective cohort study and process evaluation (CHOICE) study: a protocol.

机构信息

Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK

Obstetrics and Gynaecology, St George's University Hospitals Trust, London, UK.

出版信息

BMJ Open. 2021 May 4;11(5):e050452. doi: 10.1136/bmjopen-2021-050452.

Abstract

INTRODUCTION

The aim of the cervical ripening at home or in-hospital-prospective cohort study and process evaluation (CHOICE) study is to compare home versus in-hospital cervical ripening to determine whether home cervical ripening is safe (for the primary outcome of neonatal unit (NNU) admission), acceptable to women and cost-effective from the perspective of both women and the National Health Service (NHS).

METHODS AND ANALYSIS

We will perform a prospective multicentre observational cohort study with an internal pilot phase. We will obtain data from electronic health records from at least 14 maternity units offering only in-hospital cervical ripening and 12 offering dinoprostone home cervical ripening. We will also conduct a cost-effectiveness analysis and a mixed methods study to evaluate processes and women/partner experiences. Our primary sample size is 8533 women with singleton pregnancies undergoing induction of labour (IOL) at 39+0 weeks' gestation or more. To achieve this and contextualise our findings, we will collect data relating to a cohort of approximately 41 000 women undergoing IOL after 37 weeks. We will use mixed effects logistic regression for the non-inferiority comparison of NNU admission and propensity score matched adjustment to control for treatment indication bias. The economic analysis will be undertaken from the perspective of the NHS and Personal Social Services (PSS) and the pregnant woman. It will include a within-study cost-effectiveness analysis and a lifetime cost-utility analysis to account for any long-term impacts of the cervical ripening strategies. Outcomes will be reported as incremental cost per NNU admission avoided and incremental cost per quality adjusted life year gained.

RESEARCH ETHICS APPROVAL AND DISSEMINATION

CHOICE has been funded and approved by the National Institute of Healthcare Research Health Technology and Assessment, and the results will be disseminated via publication in peer-reviewed journals.

TRIAL REGISTRATION NUMBER

ISRCTN32652461.

摘要

介绍

家庭或医院内经阴道前列腺素制剂促宫颈成熟的前瞻性队列研究和过程评估(CHOICE)旨在比较家庭与院内经阴道前列腺素制剂促宫颈成熟,以确定家庭经阴道前列腺素制剂促宫颈成熟是否安全(主要结局为新生儿重症监护病房(NNU)收治),从女性和国家医疗服务体系(NHS)的角度来看是否可以被女性接受并且具有成本效益。

方法和分析

我们将进行一项具有内部试点阶段的前瞻性多中心观察性队列研究。我们将从至少 14 个仅提供院内经阴道前列腺素制剂促宫颈成熟的产科单位和 12 个提供地诺前列酮家庭经阴道前列腺素制剂促宫颈成熟的单位获取电子健康记录数据。我们还将进行成本效益分析和混合方法研究,以评估流程和女性/伴侣的体验。我们的主要样本量为 8533 名单胎妊娠妇女,这些妇女在 39+0 周或以上妊娠时进行引产(IOL)。为了达到这一目的并使我们的研究结果具有背景意义,我们将收集大约 41000 名在 37 周后进行 IOL 的妇女的队列数据。我们将使用混合效应逻辑回归进行 NNU 收治的非劣效性比较,并使用倾向评分匹配调整来控制治疗指征偏倚。经济分析将从 NHS 和个人社会服务(PSS)和孕妇的角度进行。它将包括一项基于研究的成本效益分析和一项终身成本效用分析,以考虑经阴道前列腺素制剂促宫颈成熟策略的任何长期影响。结果将报告为每避免收治一个 NNU 节省的增量成本和每获得一个质量调整生命年增加的增量成本。

研究伦理批准和传播

CHOICE 已获得国家卫生研究院医疗保健研究、技术评估的资助和批准,结果将通过在同行评议期刊上发表文章进行传播。

注册号

ISRCTN32652461。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d115/8098973/3638d0e3aeae/bmjopen-2021-050452f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验